A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency.
A new case of familial plasmin inhibitor (alpha2 antiplasmin) deficiency is reported. The bleeding symptoms are moderate, happening after surgery or trauma or consisting of abnormal uterine bleeding induced by hormone replacement therapy. It is easily corrected with tranexamic acid. Gene sequencing makes it possible to find a splicing donor site mutation of intron 6, leading to exon 6 skipping. Neither a shortened variant nor an abnormal plasmin interaction was found in plasma by immunoblotting, and fibrin binding is unaffected. The mutation is heterozygous, associated with an intermediate decrease of both antiplasmin activity and antigen levels, and was found in four other family members out of five tested. It is different from the five mutations previously reported. At the time of diagnosis, the patient was living in Artas, France, allowing the defect to be named plasmin inhibitor (alpha2 antiplasmin) Artas.
Hanss
Michel M L
MM
Haematology Laboratory, L Pradel Hospital, Lyon, France. michel.hanss@chu-lyon.fr
Farcis
Mathilde
M
Ffrench
Patrick O
PO
de Mazancourt
Philippe
P
Dechavanne
Marc
M
D005192:Family Health; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D007438:Introns; D008875:Middle Aged; D017354:Point Mutation; D022821:RNA Splice Sites / Q000235:genetics*; D014148:Tranexamic Acid / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000032:analysis / Q000172:deficiency / Q000235:genetics*
D022821:RNA Splice Sites; D000979:alpha-2-Antiplasmin; D014148:Tranexamic Acid